Jan 13, 2014
Galena Biopharma Acquires Mills Pharmaceuticals, LLC
Galena Biopharma , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced it has acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 , a patented, controlled release formulation of anagrelide.
AOP Orphan Pharmaceuticals AG Release: Essential Thrombocythemia (ET) ...
Anagrelide a selective platelet lowering agent is not inferior compared to hydroxyurea in preventing disease related complications in patients with WHO-ET. ANAHYDRET study data now provide evidence that anagrelide can be considered as first line therapy for lowering of platelet count in WHO-ET. High platelet counts in essential thrombocythemia can ... (more)
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
353, No. 1. , pp. 33-45. The principal feature of essential thrombocythemia, a clonal hematologic stem-cell disorder,1?4 is thrombosis, with arterial events being more common than venous events.